127100 | Allopregnanolone - CAS 516-54-1 - Calbiochem

127100
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Empirical FormulaCAS #
      C₂₁H₃₄O₂516-54-1

      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      US1127100-10MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      In Stock 
      Discontinued
      Limited Quantities Available
      Availability to be confirmed
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA natural metabolite of progesterone that is devoid of any progestational activity. Acts as a potent ligand of GABA type A receptor complexes in the CNS. Potentiates the GABA receptor-mediated chloride uptake in synaptosomes 100- to 1,000-fold more effectively than benzodiazepines or barbiturates. Causes a rapid increase in Ca2+ influx in a dose-dependent manner (EC50 =10 nM in fetal hypothalamic neurons).
          Catalogue Number127100
          Brand Family Calbiochem®
          SynonymsAllopregnan-3α-ol-20-one, 3α-Hydroxy-5α-pregnan-20-one, 3α-OH-DHP
          References
          ReferencesDayanithi, G., and Tapia-Arancibia, L. 1996. J. Neurosci. 16, 130.
          Bitran, P., et al. 1995. J. Neuroendocrinol. 7, 171.
          Calixto, E., et al. 1995. Neurosci. Lett. 195, 73.
          Genazzani, A.R., et al. 1995. Eur. J. Endocrinol. 133, 375.
          Paul, S.M., and Purdy, R.H. 1992. FASEB J. 6, 2311.
          Zaman, S.H., et al. 1992. Eur. J. Pharmacol. 225, 321.
          McEwan, B.S. 1991. Trends Pharmacol. Sci. 12, 141.
          Product Information
          CAS number516-54-1
          ATP CompetitiveN
          FormWhite solid
          Hill FormulaC₂₁H₃₄O₂
          Chemical formulaC₂₁H₃₄O₂
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetPotent ligand of GABA type A receptor complexes in the CNS
          Primary Target IC<sub>50</sub>EC50 =10 nM causing a rapid increase in Ca2+ influx in a dose-dependent manner in fetal hypothalamic neurons
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECSTU4383000
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +15°C to +30°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Certificates of Analysis

          TitleLot Number
          127100

          References

          Reference overview
          Dayanithi, G., and Tapia-Arancibia, L. 1996. J. Neurosci. 16, 130.
          Bitran, P., et al. 1995. J. Neuroendocrinol. 7, 171.
          Calixto, E., et al. 1995. Neurosci. Lett. 195, 73.
          Genazzani, A.R., et al. 1995. Eur. J. Endocrinol. 133, 375.
          Paul, S.M., and Purdy, R.H. 1992. FASEB J. 6, 2311.
          Zaman, S.H., et al. 1992. Eur. J. Pharmacol. 225, 321.
          McEwan, B.S. 1991. Trends Pharmacol. Sci. 12, 141.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision10-April-2008 RFH
          SynonymsAllopregnan-3α-ol-20-one, 3α-Hydroxy-5α-pregnan-20-one, 3α-OH-DHP
          DescriptionA natural metabolite of progesterone that is devoid of progestational activity. Functions as a potent ligand of GABA type A receptor complexes in the CNS potentiating the GABA receptor-mediated chloride uptake in synaptosomes 100- to 1000-fold more effectively than benzodiazepines or barbituates. Causes a rapid increase in Ca2+ influx in a dose-dependent manner (EC50 = 10 nM in fetal hypothalamic neurons).
          FormWhite solid
          CAS number516-54-1
          RTECSTU4383000
          Chemical formulaC₂₁H₃₄O₂
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (10 mg/ml) or Ethanol (5 mg/ml)
          Storage +15°C to +30°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          Merck USA index14, 275
          ReferencesDayanithi, G., and Tapia-Arancibia, L. 1996. J. Neurosci. 16, 130.
          Bitran, P., et al. 1995. J. Neuroendocrinol. 7, 171.
          Calixto, E., et al. 1995. Neurosci. Lett. 195, 73.
          Genazzani, A.R., et al. 1995. Eur. J. Endocrinol. 133, 375.
          Paul, S.M., and Purdy, R.H. 1992. FASEB J. 6, 2311.
          Zaman, S.H., et al. 1992. Eur. J. Pharmacol. 225, 321.
          McEwan, B.S. 1991. Trends Pharmacol. Sci. 12, 141.